Literature DB >> 18688034

Paracrine overexpression of insulin-like growth factor-1 enhances mammary tumorigenesis in vivo.

Krisztina Kovács de Ostrovich1, Isabel Lambertz, Jennifer K L Colby, Jie Tian, Joyce E Rundhaug, Dennis Johnston, Claudio J Conti, John DiGiovanni, Robin Fuchs-Young.   

Abstract

Insulin-like growth factor-1 (IGF-1) stimulates proliferation, regulates tissue development, protects against apoptosis, and promotes the malignant phenotype in the breast and other organs. Some epidemiological studies have linked high circulating levels of IGF-1 with an increased risk of breast cancer. To study the role of IGF-1 in mammary tumorigenesis in vivo, we used transgenic mice in which overexpression of IGF-1 is under the control of the bovine keratin 5 (BK5) promoter and is directed to either the myoepithelial or basal cells in a variety of organs, including the mammary gland. This model closely recapitulates the paracrine exposure of breast epithelium to stromal IGF-1 seen in women. Histologically, mammary glands from transgenic mice were hyperplastic and highly vascularized. Mammary glands from prepubertal transgenic mice had significantly increased ductal proliferation compared with wild-type tissues, although this difference was not maintained after puberty. Transgenic mice also had increased susceptibility to mammary carcinogenesis, and 74% of the BK5.IGF-1 mice treated with 7,12-dimethylbenz[a]anthracene (20 microg/day) developed mammary tumors compared with 29% of the wild-type mice. Interestingly, 31% of the vehicle-treated BK5.IGF-1 animals, but none of the wild-type animals, spontaneously developed mammary cancer. The mammary tumors were moderately differentiated adenocarcinomas that expressed functional, nuclear estrogen receptor at both the protein and mRNA levels. These data support the hypothesis that tissue overexpression of IGF-1 stimulates mammary tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18688034      PMCID: PMC2527085          DOI: 10.2353/ajpath.2008.071005

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  60 in total

Review 1.  The IGF system and breast cancer.

Authors:  D Sachdev; D Yee
Journal:  Endocr Relat Cancer       Date:  2001-09       Impact factor: 5.678

2.  Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II.

Authors:  Eva S Schernhammer; Jeff M Holly; David J Hunter; Michael N Pollak; Susan E Hankinson
Journal:  Endocr Relat Cancer       Date:  2006-06       Impact factor: 5.678

3.  Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor.

Authors:  Joan M Carboni; Adrian V Lee; Darryl L Hadsell; Bruce R Rowley; Francis Y Lee; David K Bol; Amy E Camuso; Marco Gottardis; Ann F Greer; Ching Ping Ho; Warren Hurlburt; Aixin Li; Mark Saulnier; Upender Velaparthi; Cindy Wang; Mei-Li Wen; Richard A Westhouse; Mark Wittman; Kurt Zimmermann; Brent A Rupnow; Tai W Wong
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

4.  Two promoters in expression of estrogen receptor messenger RNA in human breast cancer.

Authors:  S Hayashi; K Imai; K Suga; T Kurihara; Y Higashi; K Nakachi
Journal:  Carcinogenesis       Date:  1997-03       Impact factor: 4.944

5.  Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups.

Authors:  Kenneth C Chu; William F Anderson
Journal:  Breast Cancer Res Treat       Date:  2002-06       Impact factor: 4.872

6.  Insulin-like growth factor I triggers nuclear accumulation of cyclin D1 in MCF-7S breast cancer cells.

Authors:  Irene H L Hamelers; Richard F M A van Schaik; Jorrit Sipkema; John S Sussenbach; Paul H Steenbergh
Journal:  J Biol Chem       Date:  2002-10-02       Impact factor: 5.157

7.  Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo.

Authors:  A V Lee; J G Jackson; J L Gooch; S G Hilsenbeck; E Coronado-Heinsohn; C K Osborne; D Yee
Journal:  Mol Endocrinol       Date:  1999-05

Review 8.  The aetiology and pathogenesis of human breast cancer.

Authors:  H O Adami; I Persson; A Ekbom; A Wolk; J Pontén; D Trichopoulos
Journal:  Mutat Res       Date:  1995-12       Impact factor: 2.433

9.  Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase.

Authors:  S Kato; H Endoh; Y Masuhiro; T Kitamoto; S Uchiyama; H Sasaki; S Masushige; Y Gotoh; E Nishida; H Kawashima; D Metzger; P Chambon
Journal:  Science       Date:  1995-12-01       Impact factor: 47.728

Review 10.  Insulin-like growth factors and insulin-like growth factor binding proteins in mammary gland function.

Authors:  Emma Marshman; Charles H Streuli
Journal:  Breast Cancer Res       Date:  2002-08-29       Impact factor: 6.466

View more
  25 in total

1.  Prepubertal exposure to cow's milk reduces susceptibility to carcinogen-induced mammary tumorigenesis in rats.

Authors:  Tina S Nielsen; Galam Khan; Jennifer Davis; Karin B Michels; Leena Hilakivi-Clarke
Journal:  Int J Cancer       Date:  2011-01-01       Impact factor: 7.396

2.  Transgenic insulin-like growth factor-1 stimulates activation of COX-2 signaling in mammary glands.

Authors:  Jie Tian; Isabel Lambertz; Thomas R Berton; Joyce E Rundhaug; Kaoru Kiguchi; Stephanie H Shirley; John Digiovanni; Claudio J Conti; Susan M Fischer; Robin Fuchs-Young
Journal:  Mol Carcinog       Date:  2011-10-17       Impact factor: 4.784

3.  Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells.

Authors:  Xudong Tang; Qunzhou Zhang; Shihong Shi; Yun Yen; Xiangyong Li; Yuefei Zhang; Keyuan Zhou; Anh D Le
Journal:  Int J Cancer       Date:  2010-01-01       Impact factor: 7.396

4.  Developmental stage determines estrogen receptor alpha expression and non-genomic mechanisms that control IGF-1 signaling and mammary proliferation in mice.

Authors:  Jie Tian; Thomas R Berton; Stephanie H Shirley; Isabel Lambertz; Irma B Gimenez-Conti; John DiGiovanni; Kenneth S Korach; Claudio J Conti; Robin Fuchs-Young
Journal:  J Clin Invest       Date:  2011-12-19       Impact factor: 14.808

5.  Alcohol exposure in utero leads to enhanced prepubertal mammary development and alterations in mammary IGF and estradiol systems.

Authors:  Tiffany A Polanco; Catina Crismale-Gann; Wendie S Cohick
Journal:  Horm Cancer       Date:  2011-08       Impact factor: 3.869

6.  Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer.

Authors:  F Morgillo; F De Vita; G Antoniol; M Orditura; P P Auriemma; M R Diadema; E Lieto; B Savastano; L Festino; M M Laterza; A Fabozzi; J Ventriglia; A Petrillo; F Ciardiello; A Barbarisi; F Iovino
Journal:  Curr Oncol       Date:  2013-08       Impact factor: 3.677

Review 7.  Insulin and IGFs in obesity-related breast cancer.

Authors:  Valentina Belardi; Emily J Gallagher; Ruslan Novosyadlyy; Derek LeRoith
Journal:  J Mammary Gland Biol Neoplasia       Date:  2013-10-24       Impact factor: 2.673

8.  A high protein moderate carbohydrate diet fed at discrete meals reduces early progression of N-methyl-N-nitrosourea-induced breast tumorigenesis in rats.

Authors:  Christopher J Moulton; Rudy J Valentine; Donald K Layman; Suzanne Devkota; Keith W Singletary; Matthew A Wallig; Sharon M Donovan
Journal:  Nutr Metab (Lond)       Date:  2010-01-10       Impact factor: 4.169

9.  The protective effect of intermittent calorie restriction on mammary tumorigenesis is not compromised by consumption of a high fat diet during refeeding.

Authors:  Olga P Rogozina; Katai J Nkhata; Emily J Nagle; Joseph P Grande; Margot P Cleary
Journal:  Breast Cancer Res Treat       Date:  2013-02-28       Impact factor: 4.872

Review 10.  Mechanisms linking obesity and cancer.

Authors:  Sharon M Louie; Lindsay S Roberts; Daniel K Nomura
Journal:  Biochim Biophys Acta       Date:  2013-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.